Basic knowledge on BCR-ABL1-positive extracellular vesicles

Biomark Med. 2020 Apr;14(6):451-458. doi: 10.2217/bmm-2019-0510. Epub 2020 Apr 9.


Chronic myelogenous leukemia (CML) is a hematological malignancy characterized by the excessive proliferation of myeloid progenitors. In the case of CML, these extracellular vesicles (EVs) were shown to communicate with hematopoietic stem cells, mesenchymal stem cells, myeloid derived suppressor cells and endothelial cells determining a beneficial microenvironment for the CML clone. Moreover, as these EVs are marked through BCR-ABL1, they were shown to be useful in clinical research in determining the grade of molecular remission with further studies being needed to determine if they are better or worse at predicting CML relapse. More than this, we consider BCR-ABL1-positive EVs to represent only a stepping-stone for other malignancies that also present fusion genes that are loaded in EVs.

Keywords: BCR-ABL; cell communication; chronic myeloid leukemia; extracellular vesicles; microenvironment; microvesicles; translational medicine.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Extracellular Vesicles / genetics*
  • Fusion Proteins, bcr-abl / genetics*
  • Humans
  • K562 Cells
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
  • Tumor Microenvironment


  • BCR-ABL1 fusion protein, human
  • Fusion Proteins, bcr-abl